Commentary|Videos|February 6, 2025
Additional Potential Roles for Mirvetuximab Soravtansine and Other ADCs in Ovarian Cancer
Author(s)Floortje J. Backes, MD
Floortje J. Backes, MD, discusses other potential roles for mirvetuximab soravtansine and other antibody-drug conjugates in ovarian cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
5